Table 1.
Characteristic | Study 1
|
Study 2
|
Study 3
|
|||
---|---|---|---|---|---|---|
Controls | B2AR agonist peripherally | B2AR agonist peripherally, aCSF to the VMH | B2AR agonist peripherally, B2AR antagonist to the VMH | Controls | B2AR agonist peripherally | |
n | 5 | 5 | 8 | 8 | 4 | 4 |
Body weight (g) | 290±15 | 315±7 | 310±20 | 313±7.4 | 301±6 | 304±16 |
Plasma glucose (mmol/l) | 5.3±0.3 | 5.3±0.1 | 6.2±0.2 | 5.9±0.2 | 6.3±0.1 | 6.4±0.1 |
Insulin (pmol/l) | 62.5±7.6 | 38.9±8.3 | 132±46 | 111±47 | 60±4.8 | 61±4.8 |
Glucagon (ng/l) | 44±12 | 42±12 | 53±7.2 | 47±3.5 | 64±6 | 63±4 |
Adrenaline (pmol/l) | 890±284 | 933±213 | 912±393 | 884±218 | 442±55 | 371±180 |
Noradrenaline (pmol/l) | 1,868±360 | 1,690±337 | 2,477±449 | 2,554±662 | 851±154 | 904±65 |
Data are presented as means ± SEM